This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Philipson RG , Romero T , Wong JK , Stish BJ , Dess RT , Spratt DE , Pilar A , Reddy C , Wedde TB , Lilleby WA , Fiano R , Merrick GS , Stock RG , Demanes DJ , Moran BJ , Braccioforte M , Tran PT , Martin S , Martinez-Monge R , Krauss DJ , Abu-Isa EI , Valle L , Chong N , Pisansky TM , Choo CR , Song DY , Greco S , Deville C , McNutt T , DeWeese TL , Ross AE , Ciezki JP , Tilki D , Karnes RJ , Klein EA , Tosoian JJ , Boutros PC , Nickols NG , Bhat P , Shabsovich D , Juarez JE , Kupelian PA , Rettig MB , Berlin A , Tward JD , Davis BJ , Reiter RE , Steinberg ML , Elashoff D , Horwitz EM , Tendulkar RD , Kishan AU
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
Eur Urol. 2021 May 10
AbstractThe natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT SUMMARY: High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.
Notes1873-7560 Philipson, Rebecca G Romero, Tahmineh Wong, Jessica K Stish, Bradley J Dess, Robert T Spratt, Daniel E Pilar, Avinash Reddy, Chandana Wedde, Trude B Lilleby, Wolfgang A Fiano, Ryan Merrick, Gregory S Stock, Richard G Demanes, D Jeffrey Moran, Brian J Braccioforte, Michelle Tran, Phuoc T Martin, Santiago Martinez-Monge, Rafael Krauss, Daniel J Abu-Isa, Eyad I Valle, Luca Chong, Natalie Pisansky, Thomas M Choo, C Richard Song, Daniel Y Greco, Stephen Deville, Curtiland McNutt, Todd DeWeese, Theodore L Ross, Ashley E Ciezki, Jay P Tilki, Derya Karnes, R Jeffrey Klein, Eric A Tosoian, Jeffrey J Boutros, Paul C Nickols, Nicholas G Bhat, Prashant Shabsovich, David Juarez, Jesus E Kupelian, Patrick A Rettig, Matthew B Berlin, Alejandro Tward, Jonathan D Davis, Brian J Reiter, Robert E Steinberg, Michael L Elashoff, David Horwitz, Eric M Tendulkar, Rahul D Kishan, Amar U Journal Article Switzerland Eur Urol. 2021 May 10:S0302-2838(21)00314-6. doi: 10.1016/j.eururo.2021.04.035.